Small-scale innovation, large-scale ambition: optimizing fragment-drug conjugates

“The future of ADCs may be less about choosing one ‘perfect’ technology and more about combining the best elements of each in a Lego-like way to build truly modular, multifunctional therapies.”

In this interview, Ashling Cannon (Assistant Editor, Bioconjugation Insights) speaks with Meddy El Alaoui (CEO, AbTx), about the evolution of enzymatic bioconjugation and its role in advancing fragment-based ADC design. They discuss production challenges, scalability, and the promise of plug-and-play bioconjugation technologies for next-generation targeted therapies.

Please enter your email to access content Read now